Vascular targeting therapies for treatment of malignant disease

A detailed and useful review of vascular destabilizing agents (VDA) and their tremendous potential when applied in combination with radiotherapy was recently published. It should be of note to the cancer community that alternatives to the compounds described by Siemann et al. are available. Arsenic trioxide (ATO) is inexpensive, readily available, provides similar biologic effects, and has been studied extensively in preclinical models and clinical trials. ATO belongs to the small-molecule VDA described by Siemann et al. that acts by tubulin depolymerization. Like some of the compounds described, ATO derives from a natural source, acts preferentially on mature tumor vasculature, and causes a rapid stasis of blood flow in the tumor core after its administration. Our group was the first to demonstrate the antitumor effect of ATO and the first to show that its antitumor effect is enhanced by radiotherapy under a fractionated schema and using an orthotopic tumor model. ATO has become the preferred salvage treatment for patients with acute promyelocytic leukemia and tolerated dosages have been established. The safety and efficacy of ATO is currently being evaluated in a Phase I multicenter, dose-escalation clinical trial in combination with radiotherapy for patients with newly diagnosed malignant glioma. What distinguishes ATO from the compounds described by Siemann et al. is that it is readily available from any of a number of nonproprietary sources (Sigma-Aldrich; St. Louis, MO) at minimal cost.

[1]  Adam P Dicker,et al.  Probability of late rectal morbidity in 125I prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[2]  P. Hall,et al.  Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study , 2002, The Lancet.

[3]  K. Wallner,et al.  Dosimetric and radiographic correlates to prostate brachytherapy‐related rectal complications , 2001, International journal of cancer.

[4]  J. Roy,et al.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.

[5]  Stephen L. Brown,et al.  Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. , 2002, Cancer research.

[6]  M. Horsman,et al.  Vascular‐targeting therapies for treatment of malignant disease , 2004, Cancer.

[7]  Z. Han,et al.  Treatment of acute promyelocytic Leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies , 2003, International journal of hematology.

[8]  J L Weissfeld,et al.  Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? , 1994, The American journal of gastroenterology.

[9]  C. Song,et al.  Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. , 1999, Cancer research.

[10]  P. Walsh Variations in morbidity after radical prostatectomy. , 2002, The Journal of urology.

[11]  Kemal Tuncali,et al.  Late genitourinary and gastrointestinal toxicity after magnetic resonance image‐guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy , 2003, Cancer.

[12]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[13]  S. Mehta,et al.  Temporal trends in radical prostatectomy complications from 1991 to 1998. , 2003, The Journal of urology.

[14]  R. Gray,et al.  Efficacy of radiotherapy for ovarian ablation , 2004, Cancer.

[15]  K. Wallner,et al.  American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[16]  D. Evans,et al.  Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry , 1993, Cancer.

[17]  M. S. Tallmann Curative therapeutic approaches to APL. , 2004, Annals of hematology.

[18]  Stephen L. Brown,et al.  Arsenic Trioxide Enhances Radiation Response of 9L Glioma in the Rat Brain , 2003, Radiation research.

[19]  J. Cohen,et al.  Complications after prostate brachytherapy in the Medicare population. , 2000, Urology.

[20]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[21]  R. Stock,et al.  Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. , 2002, Brachytherapy.